Sector: Health Care
Director information for ORGANON (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Alan Ezekowitz, M.D., Ph.D. | Independent Director | 72 | ["Advisory Partner at Third Rock Ventures, LLC","Former CEO and Co-Founder of Abide Therapeutics","Former SVP and Franchise Head at Merck Research Laboratories","Advisory Partner at Third Rock Ventures, LLC since 2019","Entrepreneur in Residence at Cardinal Partners since 2011","Former President and CEO of Abide Therapeutics, Inc. (2011-2019)","Former Senior Vice President at Merck Research Laboratories (2006-2011)","Former Chief of Pediatric Services at Partners Healthcare System, Inc. (1999-2006)","Former Charles Wilder Professor of Pediatrics at Harvard Medical School (1995-2006)"] | ["Audit","ESG","PDC"] | 2026 |
| Carrie S. Cox | Executive Chair of the Board; Chairman of the Board | 68 | ["Executive Chair of Organon & Co.","Former Chief Executive Officer of Humacyte, Inc.","Former EVP of Schering-Plough","Current Chairman of Solventum Corporation","Director of Texas Instruments Inc.","Chief Executive Officer of Humacyte, Inc. (2010-2018)","Chairman of Humacyte's board (2013-2019)","Executive Vice President of Schering-Plough Corporation (2003-2009)","President of Schering-Plough’s global pharmaceutical business (2003-2009)","President of Pharmacia Corporation's global pharmaceutical business (1997-2003)","Chairman of the board of directors of Solventum Corporation"] | [] | 2026 |
| Cynthia M. Patton | General Counsel and Corporate Secretary, Tessera Therapeutics; Director | 64 | ["General Counsel and Corporate Secretary at Tessera Therapeutics","General Counsel and Secretary at Verily Life Sciences","Senior Vice President, Chief Compliance Officer at Amgen Inc.","General Counsel of SCAN Health Plan","Board member of the NAACP Legal Defense Fund","Board member of the trustees of Vassar College","Graduate of Vassar College","J.D. from George Washington University School of Law","Experience in life sciences and knowledge of data analytics"] | ["Audit"] | 2026 |
| Deborah Leone | Former Partner & Chief Operating Officer, Investment Management, Goldman Sachs Group, Inc. | 61 | ["Financial expert","Retired partner of Goldman Sachs Group, Inc.","Chief Operating Officer for Investment Management Division","Global Director of Internal Audit","Global Controller for IMD","Board member of Corebridge Financial, Inc.","Director of Goldman Sachs Bank USA","Graduate of Syracuse University with M.B.A."] | ["Audit"] | 2026 |
| Grace Puma | Director | [] | [] | 2026 | |
| Helene Gayle, M.D., M.P.H. | Director | 70 | ["President Emerita of Spelman College","Expert on global development, humanitarian, and health issues","President of Spelman College","Former President and CEO of the Chicago Community Trust","Former CEO of the McKinsey Social Initiative","Former President and CEO of CARE","20 years at the U.S. Centers for Disease Control","Director of the National Center for HIV, STD and TB Prevention","Assistant Surgeon General and Rear Admiral in the U.S. Public Health Service","Non-profit board experience","Member of the Council on Foreign Relations","Member of the National Academy of Medicine","Member of The American Academy of Arts and Sciences","Member of the American Public Health Association","Significant board experience"] | ["Audit","PDC","Talent (Chair)","ESG"] | 2026 |
| Joseph Morrissey | Interim CEO; Interim Chief Executive Officer | 61 | ["Responsible for Organon’s global manufacturing and supply chain capabilities","Over 30 years of experience at Merck","M.B.A. from Villanova University","Bachelor’s degree in engineering from Lafayette College"] | [] | 2026 |
| Juliana Drinane | Interim Head of Manufacturing and Supply | 55 | ["Served as Head of Global Supply Chain Management at Organon","28 years at Merck in various leadership roles","Background in pharmaceutical industry with 30+ years of experience","Received a BS in Chemical Engineering with Honors from Lafayette College"] | [] | 2026 |
| Matthew Walsh | Executive Vice President and Chief Financial Officer | 59 | ["Develops and executes Organon's financial strategy","CFO at Allergan plc from 2018 to 2020","CFO at Catalent, Inc. from 2008 to 2018","CFA Charterholder","M.B.A. and bachelor’s degree in chemical engineering from Cornell University"] | ["Audit Committee"] | 2026 |
| Philip Ozuah, M.D., Ph.D. | President and Chief Executive Officer, Montefiore Medicine | 63 | ["President and Chief Executive Officer of Montefiore Medicine","President of Montefiore Health System (2018-2019)","Executive Vice President and Chief Operating Officer of Montefiore Health System (2012-2018)","Chairman of the Department of Pediatrics (2005-2014)","Professor in the Departments of Pediatrics and Epidemiology and Population Health since 1992","Board member of The Cigna Group","Board member of Montefiore Hospital"] | ["Audit","Talent","PDC"] | 2026 |
| Ramona Sequeira | Former President, Global Portfolio Division, Takeda Pharmaceutical Company | 60 | ["Significant general management","Commercial strategy and execution","Business development","Integration","Portfolio development","Product launch experience"] | ["Talent"] | 2026 |
| Robert Essner | Lead Independent Director; Lead Director | 78 | ["Executive in Residence and Adjunct Professor at Columbia Business School","Former Chairman, Chief Executive Officer and President of Wyeth Pharmaceuticals, Inc.","Chairman of Wyeth Pharmaceuticals (2003-2008)","Chief Executive Officer of Wyeth Pharmaceuticals (2001-2007)","President of Wyeth Pharmaceuticals (2000-2006)","Chief Operating Officer of Wyeth Pharmaceuticals (2000-2001)","Executive Vice President of Wyeth Pharmaceuticals (1997-2000)","Senior Advisor of Global Healthcare at The Carlyle Group (2009-2019)","Executive in Residence and Adjunct Professor of Business at Columbia Business School"] | ["Audit","Talent","ESG","PDC"] | 2026 |
| Rochelle (“Shelly”) B. Lazarus | 78 | ["Chairman Emeritus of Ogilvy & Mather since 2012","Chairman of Ogilvy & Mather (2008-2012)","Chairman and Chief Executive Officer of Ogilvy & Mather (1996-2008)","President of Ogilvy & Mather Direct North America","President of Ogilvy & Mather New York","Board of directors of Blackstone, Inc.","Board of directors of Rockefeller Capital Management","Former board of directors of General Electric Company (2000-2018)","Former board of directors of Merck (2004-2020)","Vice chair and trustee of the New York Presbyterian Hospital","Member of the board of overseers of Columbia Business School","Graduate of Smith College","M.B.A. from Columbia University","Strong background in reputation management and consumer insight","Chairman Emeritus of Ogilvy & Mather"] | ["ESG","Audit"] | 2026 | |
| Shalini Sharp | Former Executive Vice President and Chief Financial Officer, Ultragenyx Pharmaceutical Inc.; Director | 51 | ["Executive Vice President and Chief Financial Officer of Ultragenyx Pharmaceutical Inc. (2012-2020)","Chief Financial Officer of Agenus Inc. (2006-2012)","Various finance, corporate development and corporate strategy roles at Agenus Inc. (2003-2006)","Director of Neurocrine Biosciences, Inc.","Director of BeOne Medicines (previously BeiGene, Ltd.)","Director of Septerna, Inc.","Former director of Mirati Therapeutics (2021-2024)","Former director of Sutro Biopharma, Inc. (2018-2023)","Former director of Precision Biosciences, Inc. (2018-2022)","Former director of Array BioPharma Inc. (2017-2019)","Former director of Agenus Inc. (2012-2018)","Strategic planning and chief of staff to the chairman of the board of directors of Elan Pharmaceuticals","Management consultant at McKinsey & Company","Investment banker at Goldman Sachs, specializing in healthcare","M.B.A. and undergraduate degrees from Harvard University"] | ["ESG","Audit (Chair)","PDC"] | 2026 |
